A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs PXL 770 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Poxel
- 05 Aug 2019 According to a Poxel media release, results from the study are anticipated in the second quarter of 2020.
- 01 Apr 2019 Status changed from not yet recruiting to recruiting, according to a Poxel media release.
- 01 Apr 2019 According to a Poxel media release, results from this study are anticipated in the first half of 2020.